Wednesday, July 24, 2024 5:20:49 PM
It was certainly never going to be case that the MHRA would abdicate their regulatory responsibility, and place the nod of approval in the hands of commercially incentivised entities, nor base it solely on the printed opinion in an online magazine article.
As you can imagine, the level of forensic auditing of a company wishing to supply cancer treatments to the NHS, at the premium demanded, requires a damn sight more than just vested interest hearsay about how great it is.
With that in mind, some here need to wake the F up about the likelihood of getting an MAA granted, and the chances of NICE reimbursements.
There is also the more abstract concept of a supplier's fitness, both ethically and financially, to operate in partnership with the NHS, who's primary role and purpose, is to safe guard both the physical and mental well being of it's most vulnerable patients.
Under pinning that, is the provision of treatment at a price point, that will not impact the ability of our healthcare system to treat the majority.
As you can imagine, the level of forensic auditing of a company wishing to supply cancer treatments to the NHS, at the premium demanded, requires a damn sight more than just vested interest hearsay about how great it is.
With that in mind, some here need to wake the F up about the likelihood of getting an MAA granted, and the chances of NICE reimbursements.
There is also the more abstract concept of a supplier's fitness, both ethically and financially, to operate in partnership with the NHS, who's primary role and purpose, is to safe guard both the physical and mental well being of it's most vulnerable patients.
Under pinning that, is the provision of treatment at a price point, that will not impact the ability of our healthcare system to treat the majority.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
